ANI Pharmaceuticals, Inc. (ANIP) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $80.00 (+0.69%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jan 16, 2026 | Vamil Divan | Guggenheim | $124.00 | +55.0% |
| Sep 17, 2025 | Brandon Folkes | H.C. Wainwright | $121.00 | +51.2% |
| Sep 8, 2025 | Vamil Divan | Guggenheim | $114.00 | +42.5% |
| Aug 8, 2025 | David Amsellem | Piper Sandler | $94.00 | +17.5% |
| Sep 18, 2024 | Gary Nachman | Raymond James | $83.00 | +3.8% |
| Sep 11, 2024 | Les Sulewski | Truist Financial | $60.00 | -25.0% |
| Jun 26, 2024 | Oren Livnat | H.C. Wainwright | $94.00 | +17.5% |
| May 13, 2024 | Oren Livnat | H.C. Wainwright | $87.00 | +8.8% |
Top Analysts Covering ANIP
ANIP vs Sector & Market
| Metric | ANIP | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.24 | 2.41 |
| Analyst Count | 2 | 8 | 18 |
| Target Upside | +55.0% | +1150.2% | +14.9% |
| P/E Ratio | 23.88 | 6.85 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $255M | $262M | $268M | 5 |
| 2026-09-30 | $282M | $290M | $296M | 2 |
| 2026-12-31 | $317M | $326M | $333M | 2 |
| 2027-03-31 | $263M | $271M | $277M | 2 |
| 2027-06-30 | $287M | $295M | $301M | 2 |
| 2027-09-30 | $301M | $310M | $316M | 2 |
| 2027-12-31 | $320M | $329M | $336M | 2 |
| 2028-12-31 | $1.29B | $1.30B | $1.32B | 5 |
| 2029-12-31 | $1.32B | $1.38B | $1.41B | 2 |
| 2030-12-31 | $1.43B | $1.50B | $1.54B | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $1.99 | $2.15 | $2.31 | 5 |
| 2026-09-30 | $2.43 | $2.52 | $2.59 | 1 |
| 2026-12-31 | $2.92 | $3.02 | $3.11 | 1 |
| 2027-03-31 | $1.91 | $1.98 | $2.04 | 1 |
| 2027-06-30 | $2.44 | $2.53 | $2.60 | 1 |
| 2027-09-30 | $2.78 | $2.88 | $2.97 | 1 |
| 2027-12-31 | $3.21 | $3.33 | $3.42 | 1 |
| 2028-12-31 | $11.77 | $12.45 | $12.89 | 3 |
| 2029-12-31 | $11.95 | $12.64 | $13.09 | 2 |
| 2030-12-31 | $12.66 | $13.38 | $13.86 | 2 |
Frequently Asked Questions
What is the analyst consensus for ANIP?
The consensus among 2 analysts covering ANI Pharmaceuticals, Inc. (ANIP) is Buy with an average price target of $107.00.
What is the highest price target for ANIP?
The highest price target for ANIP is $124.00, set by Vamil Divan at Guggenheim on 2026-01-16.
What is the lowest price target for ANIP?
The lowest price target for ANIP is $60.00, set by Les Sulewski at Truist Financial on 2024-09-11.
How many analysts cover ANIP?
2 analysts have issued ratings for ANI Pharmaceuticals, Inc. in the past 12 months.
Is ANIP a buy or sell right now?
Based on 2 analyst ratings, ANIP has a consensus rating of Buy (2.00/5) with a +55.0% upside to the consensus target of $107.00.
What are the earnings estimates for ANIP?
Analysts estimate ANIP will report EPS of $2.15 for the period ending 2026-06-30, with revenue estimated at $262M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.